By what percentage does ezetimibe lower LDL cholesterol when used as monotherapy?

As monotherapy, the drug reduces overall hypercholesterolemia by 18%. The effect is achieved by selectively inhibiting the intestinal absorption of dietary and biliary cholesterol through blockade of the specific NPC1L1 transporter.

What are the absolute contraindications to prescribing ezetimibe?

In cases of liver cirrhosis, ezetimibe therapy should be discontinued if signs of decompensation corresponding to Child-Pugh class B–C appear. When combining ezetimibe with HMG-CoA reductase inhibitors, monitoring of transaminases (ALT, AST) is mandatory; decisions regarding discontinuation or dose adjustment upon elevation are made according to statin prescribing guidelines.

With which lipid-lowering agents, other than statins, can ezetimibe be rationally combined?

Ezetimibe can be used in combination with PCSK9 inhibitors (such as alirocumab and evolocumab) or inclisiran, especially when target LDL-C levels are not reached or in cases of statin intolerance.

What is the primary molecular target of ezetimibe?

The primary target is the specific NPC1L1 transporter protein on the apical membrane of enterocytes, which is responsible for transporting cholesterol into the cell.

What is the role of ABCG5 and ABCG8 transporters?

These ATP-binding cassette transporters are stimulated by the drug to pump sterols out of the enterocyte back into the intestinal lumen.

Which statin is most commonly combined with ezetimibe?

Combination therapy with simvastatin is particularly common and effective for managing hyperlipidemia.

Home › Pharmacology › Ezetimibe

Ezetimibe

Ezetimibum

For medical students2 min readUpdated 2026-10-10

Ezetimibe is a modern lipid-lowering medication that selectively inhibits the intestinal absorption of exogenous cholesterol. It blocks the NPC1L1 transporter protein on the apical membrane of enterocytes, thereby reducing blood cholesterol levels.

Drug ClassCholesterol absorption inhibitor, lipid-lowering agent

Molecular TargetNPC1L1 cholesterol transporter in the enterocyte brush border

Half-lifeApproximately 22 hours due to enterohepatic recirculation

EfficacyMonotherapy reduces hypercholesterolemia by about 18%

Cellular Mechanism of Action

The drug acts in the small intestine at the level of the villi and the enterocyte brush border. Epithelial cells are joined by tight junctions that maintain membrane polarity. On the apical surface, ezetimibe specifically interferes with sterol transport:

Inhibition of Uptake: The drug blocks the specific NPC1L1 (Niemann-Pick C1-Like 1) transporter, halting the uptake of dietary and biliary cholesterol from the intestinal lumen into the epithelial cell.
Activation of Efflux: It stimulates the ATP-binding cassette transporters ABCG5 and ABCG8, which actively pump sterols back into the intestinal lumen.

As a result, cholesterol influx into enterocytes and subsequently into the liver via chylomicrons is decreased.

Pharmacokinetic Properties

Once inside the body, the drug undergoes important transformations:

About 80% of the dose is metabolized to form an active metabolite, ezetimibe-glucuronide.
The compound actively participates in enterohepatic circulation.
Due to continuous recirculation between the intestine and the liver, the drug is retained in the body for a long time, with a half-life of approximately 22 hours.

Clinical Application and Combinations

Ezetimibe is available as a single-ingredient drug and as part of combination therapies:

Monotherapy: Reduces hypercholesterolemia by approximately 18%.
Combinations: Maximum efficacy is achieved when co-administered with simvastatin.
Additional Effect: The drug exhibits pleiotropic anti-inflammatory activity, lowering plasma C-reactive protein concentrations by more than half.

Mnemonic

Ezetimibe = «Ezet-NPC» (blocks entry via NPC1L1, pumps back out into the intestinal lumen via ABCG5/8).

Frequently asked questions

By what percentage does ezetimibe lower LDL cholesterol when used as monotherapy?: As monotherapy, the drug reduces overall hypercholesterolemia by 18%. The effect is achieved by selectively inhibiting the intestinal absorption of dietary and biliary cholesterol through blockade of the specific NPC1L1 transporter.
What are the absolute contraindications to prescribing ezetimibe?: In cases of liver cirrhosis, ezetimibe therapy should be discontinued if signs of decompensation corresponding to Child-Pugh class B–C appear. When combining ezetimibe with HMG-CoA reductase inhibitors, monitoring of transaminases (ALT, AST) is mandatory; decisions regarding discontinuation or dose adjustment upon elevation are made according to statin prescribing guidelines.
With which lipid-lowering agents, other than statins, can ezetimibe be rationally combined?: Ezetimibe can be used in combination with PCSK9 inhibitors (such as alirocumab and evolocumab) or inclisiran, especially when target LDL-C levels are not reached or in cases of statin intolerance.
What is the primary molecular target of ezetimibe?: The primary target is the specific NPC1L1 transporter protein on the apical membrane of enterocytes, which is responsible for transporting cholesterol into the cell.
What is the role of ABCG5 and ABCG8 transporters?: These ATP-binding cassette transporters are stimulated by the drug to pump sterols out of the enterocyte back into the intestinal lumen.
Which statin is most commonly combined with ezetimibe?: Combination therapy with simvastatin is particularly common and effective for managing hyperlipidemia.

Go deeper

Role of tight junctions (zonula occludens) in maintaining enterocyte polarity
Structure and function of chylomicrons in exogenous lipid transport
Mechanisms of drug enterohepatic circulation
Pleiotropic effects of lipid-lowering agents and reduction of C-reactive protein
Comparative characteristics of monotherapy versus combination regimens in dyslipidemias